Chronic liver disease
Reading File
Finding Sources
Finding Sources
Searching PubMed
"chronic liver disease" AND management
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
I now have comprehensive material from multiple authoritative textbooks. Let me compile the full detailed answer.
Chronic Liver Disease (CLD)
Definition and Overview
Chronic liver disease (CLD) refers to a progressive deterioration of liver function over a period of more than 6 months, encompassing a spectrum from hepatic inflammation and fibrosis through to cirrhosis and end-stage liver failure. It is the 12th leading cause of death in the USA, and among persons aged 45-64, cirrhosis is the 3rd leading cause of death. In the UK, liver disease is the 3rd leading cause of premature death, with deaths increasing 400% since 1970. Crucially, around 90% of liver disease is potentially preventable, yet 75% of patients present with late-stage disease.
- Bailey and Love's Short Practice of Surgery 28e, p. 1216
- Sleisenger and Fordtran's GI and Liver Disease
Aetiology
The most common causes worldwide include:
| Category | Examples |
|---|---|
| Viral | Hepatitis B, Hepatitis C, Hepatitis D |
| Alcohol-related | Alcoholic steatohepatitis, alcoholic cirrhosis |
| Metabolic / steatotic | Non-alcoholic fatty liver disease (NAFLD) / MASH (metabolic-associated steatohepatitis) |
| Autoimmune | Autoimmune hepatitis, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) |
| Genetic / metabolic | Hereditary hemochromatosis (HFE mutation C282Y), Wilson's disease, alpha-1 antitrypsin deficiency |
| Cholestatic | PSC (associated with ulcerative colitis), PBC |
| Vascular | Budd-Chiari syndrome |
| Drug-induced | Methotrexate, amiodarone, isoniazid |
| Cryptogenic | No identifiable cause |
Hereditary Hemochromatosis (HH): The most common genetic form. It is autosomal recessive, caused by the C282Y mutation of the HFE gene (found in 85-90% of northern European patients). Iron overload affects liver, pancreas, pituitary, heart, and joints. Non-HFE forms include mutations in hemojuvelin (HJV), hepcidin (HAMP), TFR2, and ferroportin - juvenile forms (HJV/HAMP mutations) present in childhood.
Primary Sclerosing Cholangitis (PSC): Chronic cholestatic disease of unknown aetiology, associated with ulcerative colitis. It produces progressive inflammation and fibrosis of intra- and extrahepatic biliary tree. Mainly affects young men in their thirties (1.5/100,000 men; 0.5/100,000 women). There is no specific treatment; most progress to fatal liver failure. Strong predisposition to cholangiocarcinoma and gallbladder cancer. Liver transplantation is the only option for diffuse disease.
- Bailey and Love's 28e; Harrison's Principles 22e (2025)
Pathophysiology
The core pathway involves:
- Hepatocellular injury (viral, toxic, metabolic, immune-mediated)
- Inflammation - cytokine release, immune activation
- Hepatic stellate cell activation - progressive collagen deposition
- Fibrosis - architectural distortion
- Cirrhosis - diffuse nodular regeneration surrounded by fibrous septa
Portal hypertension develops as a result of increased intrahepatic resistance plus increased portal venous inflow (splanchnic vasodilatation), driving the major complications.
Clinical Features
Symptoms
- Lethargy and weakness (common, often precede jaundice)
- Jaundice (impaired glucuronyl conjugation and biliary excretion of bilirubin)
- Abdominal distension (ascites)
- Mental status changes (hepatic encephalopathy)
Signs
Skin/vascular:
- Spider naevi (cutaneous vascular abnormalities that blanch on pressure; caused by hyperestrogenism)
- Palmar erythema, leukonychia (white nails), finger clubbing
- Jaundice, bruising (coagulopathy)
Endocrine:
- Hypogonadism, gynaecomastia (altered sex hormone metabolism)
Neurological:
- Hepatic encephalopathy: memory impairment, confusion, personality changes, altered sleep patterns, slow slurred speech
- Asterixis (flapping tremor - most useful clinical sign): elicited by asking the patient to extend arms while hyperextending wrist joints
- Peripheral sensorimotor neuropathy (numbness, tingling, distal lower limbs) in chronic liver failure
Abdomen:
- Ascites: detected by fluid thrill or shifting dullness (late feature)
- Splenomegaly (portal hypertension)
- Caput medusae
General:
- Sarcopenia and wasting (protein catabolism)
- Hyperdynamic circulation: high cardiac output, large pulse volume, low BP, warm extremities, fever
Harrison's 22e; Bailey and Love's 28e
Investigations
Liver Function Tests (LFTs)
- Aminotransferases (AST, ALT): detect hepatocellular injury, not true "function"
- Bilirubin: elevated in jaundice; reflects conjugation and excretion capacity
- Albumin: low in advanced disease (reduced synthetic function)
- Prothrombin time / INR: prolonged in advanced disease
- Alkaline phosphatase, GGT: elevated in cholestatic disease
Noninvasive Fibrosis Assessment
| Test | Parameters | Advanced Fibrosis | Cirrhosis |
|---|---|---|---|
| APRI | AST, platelet count | >1 | >1.5 |
| FIB-4 | Age, AST, ALT, platelet count | >1.45 | >3.25 |
| FibroTest | Haptoglobin, α2-macroglobulin, ApoA1, GGT, bilirubin | >0.45 | >0.63 |
| Transient Elastography (TE) | Shear wave speed | >7.3 kPa | >15 kPa |
| ARFI | Acoustic radiation force | >1.3 m/s | >1.87 m/s |
Note: Elastography measures liver stiffness - not fibrosis per se - and can be affected by inflammation, edema, and hepatocyte necrosis.
Liver Biopsy
- Gold standard for grading (activity) and staging (fibrosis)
- METAVIR scale: 0-4; Ishak scale: 0-6
- Not essential when diagnosis is clinically clear (e.g., varices + ascites + history of CLD)
Imaging
-
Ultrasound: first-line; coarse echotexture, nodularity, splenomegaly, ascites, portal vein diameter
-
CT/MRI: better for HCC detection and vascular anatomy
-
MRCP: for biliary tree assessment (PSC, PBC)
-
Harrison's 22e, pp. 792-801; Sleisenger and Fordtran's
Staging
Natural History of Cirrhosis (Sleisenger 4-stage model)
| Stage | Features | Prognosis |
|---|---|---|
| Stage 1 | No ascites, no varices | Compensated |
| Stage 2 | Varices, no bleeding, no ascites | Compensated |
| Stage 3 | Ascites ± varices | Decompensated |
| Stage 4 | Variceal bleeding ± ascites | Decompensated |
- Compensated cirrhosis: median survival 9-12 years; 5-fold increased mortality risk vs. general population
- Decompensated cirrhosis: median survival ~2 years; 10-fold increased mortality risk
- Overall cirrhosis survival: 66% at 1 year, 38% at 5 years, 22% at 10 years (Danish cohort)
Child-Pugh Score
Assesses 5 parameters: bilirubin, albumin, INR/PT, ascites, and encephalopathy.
| Class | Score | 1-year survival |
|---|---|---|
| A | 5-6 | ~100% |
| B | 7-9 | ~80% |
| C | ≥10 | ~45% |
Class C cirrhosis: surgery should be avoided (prohibitive mortality).
MELD Score
Model for End-Stage Liver Disease: based on serum bilirubin, creatinine, and INR. Currently used by UNOS/OPTN to prioritize patients for liver transplantation. Superior to Child-Pugh for predicting short-term mortality in decompensated disease.
- Harrison's 22e; Sleisenger and Fordtran's; Tietz Textbook of Laboratory Medicine 7e
Complications
1. Portal Hypertension and Variceal Hemorrhage
- Most feared complication; esophageal varices rupture
- Diagnosis: upper GI endoscopy (screening recommended in all cirrhotic patients)
- Management: beta-blockers (propranolol/carvedilol) for primary prophylaxis; endoscopic band ligation; TIPS (Transjugular Intrahepatic Portosystemic Shunt)
2. Ascites
- First manifestation of decompensation in 50-60% of patients
- Caused by portal hypertension + sodium retention + reduced oncotic pressure
- Management: sodium restriction, spironolactone ± furosemide, large-volume paracentesis, TIPS for refractory ascites
3. Spontaneous Bacterial Peritonitis (SBP)
- Infection of ascitic fluid without a surgical cause
- Diagnosis: ascitic fluid PMN count >250 cells/mm³
- Treatment: cefotaxime or ceftriaxone; albumin infusion reduces hepatorenal syndrome risk
4. Hepatic Encephalopathy
Graded I to IV:
- Grade 1: Inverted sleep pattern, agitation, forgetfulness, irritability, apraxia
- Grade 2: Lethargy, time/place disorientation, personality change, ataxia
- Grade 3: Somnolence to semi-stupor but responds to verbal stimuli, hyperactive reflexes, asterixis
- Grade 4: Coma
Management: lactulose (first-line), rifaximin (add-on/maintenance), treat precipitating factors (infection, GI bleed, constipation, drugs), dietary protein not restricted in most cases.
5. Hepatorenal Syndrome (HRS)
- Functional renal failure in advanced cirrhosis
- Type 1: rapid deterioration (doubling of creatinine to >2.5 mg/dL in <2 weeks); poor prognosis
- Type 2: slower course, associated with refractory ascites
- Management: terlipressin + albumin; definitive treatment is liver transplantation
6. Portopulmonary Hypertension / Hepatopulmonary Syndrome
- Hepatopulmonary syndrome: intrapulmonary vascular dilatation causing hypoxemia
- Portopulmonary hypertension: elevated pulmonary arterial pressure in the setting of portal hypertension
7. Hepatocellular Carcinoma (HCC)
- Major complication of cirrhosis, regardless of aetiology
- Surveillance: liver ultrasound every 6 months ± AFP in all cirrhotic patients
- Risk especially high with HBV, HCV, alcohol, NASH
Sleisenger; Harrison's 22e; Sabiston Surgery
Management
General Principles (Harrison's 22e)
- Alcohol: Abstinence mandatory in alcohol-related disease and cirrhosis; minimize in all CLD
- Vaccinations: All CLD patients should receive Hepatitis A and Hepatitis B vaccines (if not immune); screen for Hepatitis C; follow CDC adult vaccination schedule
- Medications: Use with caution; drug-induced hepatotoxicity can exacerbate CLD; suspect any drug in unexplained decompensation
- Surveillance: Endoscopy for varices; liver ultrasound every 6-12 months for HCC in cirrhotic patients
Disease-Specific Treatments
| Aetiology | Specific Treatment |
|---|---|
| Hepatitis B | Tenofovir or entecavir (nucleos(t)ide analogues) |
| Hepatitis C | Direct-acting antivirals (DAAs): cure rates >95% |
| Alcohol-related | Abstinence; corticosteroids/pentoxifylline in acute alcoholic hepatitis |
| NAFLD/MASH | Weight loss, metabolic syndrome management; resmetirom approved for MASH |
| Autoimmune hepatitis | Prednisolone ± azathioprine |
| PBC | Ursodeoxycholic acid (UDCA); obeticholic acid in refractory cases |
| PSC | No effective medical treatment; liver transplantation |
| Hereditary hemochromatosis | Regular venesection (phlebotomy) |
| Wilson's disease | D-penicillamine or trientine; zinc maintenance |
Liver Transplantation
- Definitive treatment for end-stage liver disease
- Indications based on MELD score ≥15 or development of complications
- King's College Criteria used for acute-on-chronic liver failure prognosis:
- Paracetamol: pH <7.30, OR all of INR >6.5, creatinine >301 µmol/L, Grade III/IV encephalopathy
- Non-paracetamol: INR >6.5, OR 3 of 5 criteria (age <10 or >40, non-A non-B aetiology, jaundice-to-encephalopathy >7 days, PT >50s, bilirubin >300 µmol/L)
Harrison's 22e; Bailey and Love's 28e; Current Surgical Therapy 14e
Summary: Important Rare Chronic Liver Conditions
| Condition | Typical Presentation |
|---|---|
| Primary sclerosing cholangitis | Abnormal LFTs, pruritus, jaundice |
| Primary biliary cirrhosis/cholangitis | Malaise, lethargy, pruritus, abnormal LFTs |
| Budd-Chiari syndrome | Ascites, pain, abdominal distension |
| Caroli's disease | Abdominal pain, sepsis, biliary obstruction |
| Simple liver cysts | Coincidental finding, pain, palpable mass |
| Polycystic liver disease | Hepatomegaly, pain |
Bailey and Love's 28e
Recent evidence note (PubMed 2024-2026): A 2025 meta-analysis (PMID 40204206) confirms high global prevalence of steatotic liver disease and its subtypes, underlining MASH as a growing driver of CLD worldwide. A 2024 systematic review (PMID 39471468) highlights that social disadvantage significantly worsens CLD outcomes, reinforcing the need for health equity in management.
This is a shared conversation. Sign in to Orris to start your own chat.